LB881 Clinical utility of dermoscopy and 31-gene expression profiling by dermatology providers in melanoma management care

Abstract

A 31-gene expression profile (31-GEP) test that predicts metastatic risk in patients with cutaneous malignant melanoma (CMM) has previously been validated and is available for clinical use. The test dichotomizes patients into lower risk and higher risk groups based on differences that correspond to unique genetic expression pattern. Although the impact of such a test on dermatology provider’s clinical decision-making has been studied, little is known about whether there exists an association between certain clinical features, such as dermoscopy, and 31-GEP results.